Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-25T07:20:19.275Z Has data issue: false hasContentIssue false
  • English
  • Français

Preparing for Pandemic Influenza: Should Hospitals Stockpile Oseltamivir?

Published online by Cambridge University Press:  21 June 2016

Sandro Cinti ,
Carol Chenoweth  and
Arnold S. Monto
Sandro Cinti*
Affiliation:
Division of Infectious Diseases, University of Michigan Health System, Ann Arbor, Michigan Ann Arbor VA Health Systems, Ann Arbor, Michigan
Carol Chenoweth
Affiliation:
Division of Infectious Diseases, University of Michigan Health System, Ann Arbor, Michigan Department of Infection Control and Epidemiology, University of Michigan Health System, Ann Arbor, Michigan University of Michigan School of Public Health, Ann Arbor, Michigan
Arnold S. Monto
Affiliation:
University of Michigan School of Public Health, Ann Arbor, Michigan
*
Infectious Diseases, University of Michigan Hospitals/Ann Arbor VA Health Systems, 2215 Fuller Rd., Ann Arbor, MI 48105, [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

The outbreak of H5N1 avian influenza in Asia has reignited concerns about an influenza pandemic. It is clear that influenza vaccine will be in short supply (or nonexistent) early in an influenza pandemic. Without vaccine, the role of antiviral agents, especially oseltamivir, in treatment and prophylaxis is of paramount importance. Unfortunately, the government cannot possibly stockpile enough oseltamivir to provide long-term prophylaxis or treatment for every healthcare worker in the United States. We think that hospitals should consider stockpiling oseltamivir, and we provide a strategy for doing so at a reasonable cost.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 26 , Issue 11 , November 2005 , pp. 852 - 854
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Crosby, A. America's Forgotten Pandemic. Cambridge, UK: Cambridge University Press; 1989.Google Scholar
2.World Health Organization. WHO: Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Since 28 January 2004. Geneva: World Health Organization; 2003. Available at www.who.int/csr/disease/avian_influenza/country/cases_table_2005_04_14/en/index.html. Accessed June 30,2005.Google Scholar
3.Schoch-Spana, M. Implications of pandemic influenza for bioterrorism response. Clin Infect Dis 2000;31:1409–1413.Google Scholar
4.Meitzer, ML, Cox, NJ, Fukuda, K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5:659–672.Google Scholar
5.Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2003;52(RR-08):1–50.Google Scholar
6.World Health Organization. WHO guidelines on the use of vaccines and antivirals during influenza pandemics. Global Health Security: Epidemic Alert and Response 2004:1–11.Google Scholar
7.Patriarca, PA, Cox, NJ. Influenza pandemic preparedness plan for the United States./Infect Dis 1997;176(suppl 1):S4–S7.Google Scholar
8.Stohr, K, Esveld, M. Public health: will vaccines be available for the next influenza pandemic? Science 2004;306:2195–2196.CrossRefGoogle ScholarPubMed
9.Taubenberger, JK, Reid, AH, Fanning, TG. Capturing a killer flu virus. Sci Am 2005;292:48–57.CrossRefGoogle ScholarPubMed
10.Moser, MR, Bender, TR, Margolis, HS, Nable, GR, Kendal, AP, Ritter, DG. An outbreak of influenza aboard a commercial airliner. Am J Epidemiol 1979;110:1–6.CrossRefGoogle ScholarPubMed
11.Saigado, CD, Farr, BM, Hall, KK, Hayden, FG. Influenza in the acute hospital setting. Lancet Infect Dis 2002;2:145–155.Google Scholar
12.Peiris, JSM, Chu, CM, Cheng, VCC, et al.Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1519–1520.Google Scholar
13.Gopalakrishna, G, Choo, P, Leo, YS, et al.SARS transmission and hospital containment. Emerg Infect Dis 2004;10:395–400.CrossRefGoogle ScholarPubMed
14.Chotpitayasunondh, T, Ungchusak, K, Hanshaoworakul, W, et al.Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 2005;11:201–208.Google Scholar
15.Hien, TT, Liem, NT, Dung, NT, et al.Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004;350:1179–1188.Google Scholar
16.Wainright, PO, Perdue, ML, Brugh, M, et al.Amantadine resistance among hemagglutinin subtype 5 strains of avian influenza virus. Avian Dis 1991;35:31–39.Google Scholar
17.Saito, R, Oshitani, H, Masuda, H, Suzuki, H. Detection of amantadine-re-sistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J Clin Microbiol 2002;40:84–88.Google Scholar
18.Fauci, A. Preparing for pandemic flu. The Washington Times. March 3, 2005.Google Scholar
19.Ward, P, Smith, I, Small, J, Suter, P, Dutkowski, R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. JAnti-microb Chemother 2005;55(suppl I):i5–i21.Google Scholar
20.Brady, MT, Sears, SD, Pacini, DL, et al.Safety and prophylactic efficacy of low-dose rimantidine in adults during an influenza A epidemic. An-timicrob Agents Chemother 1990;34:1633–1636.Google Scholar
21.Shilling, M, Povinelli, L, Krause, P, et al.Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998;16:1771–1774.CrossRefGoogle Scholar
22.Hayden, FG, Altmar, RL, Schilling, M, et al.Use of the selective neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336–1343.Google Scholar
23.Bowles, SK, Lee, W, Simor, AE, et al.Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002;50:608–616.Google Scholar
24.Longini, IM, Halloran, ME, Nizam, A. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004;159:623–633.Google Scholar
25.Kaiser, L, Wat, C, Mills, T, Mahoney, P, Ward, P, Hayden, F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667–1672.Google Scholar
26.Whitley, RJ, Hayden, FG, Reisinger, KS, et al.Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127–133.Google Scholar
27.Hayden, FG. Pandemie influenza: is an antiviral response realistic? Pediatr Infect Dis J 2004;23(suppl):S262–S269.Google Scholar